Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients

A. Corley, L. R. Caruana, A. G. Barnett, O. Tronstad and J. F. Fraser

1 Critical Care Research Group, The Prince Charles Hospital and University of Queensland, Rode Rd, Chermside, QLD 4032, Australia
2 Institute of Health and Biomedical Innovation, School of Public Health, Queensland University of Technology, 60 Musk Avenue, Kelvin Grove, QLD 4059, Australia
* Corresponding author. E-mail: amanda.corley@health.qld.gov.au

Pulmonary complications after cardiac surgery are common and are associated with adverse outcomes, including prolonged mechanical ventilation times, increased use of sedation, increased risk of ventilator-associated pneumonia, and prolonged intensive care unit and hospital lengths of stay. Alveolar collapse and atelectasis is observed in up to 90% of post-surgical cases and subsequently results in a reduction in functional residual capacity (FRC) of ~20%. Physiotherapy and early mobilization may provide some benefit, but respiratory dysfunction is still commonplace. Non-invasive ventilation can be useful in avoiding reintubation in such patients, but this treatment prevents early mobilization; is associated with gastric distension which may further reduce FRC; restricts effective communication and oral nutrition; and is poorly tolerated in some patients.

High-flow nasal cannulae (HFNCs) deliver high-flow humidified air and oxygen via wide-bore nasal cannulae at a prescribed fraction of inspired oxygen (FIO₂). Whereas conventional nasal prongs are generally limited to flows of 5 litre min⁻¹ due to the potential drying effects of cold oxygen on the nasal mucosa, oxygen at up to 50 litre min⁻¹ may be delivered when the warmed gas is optimally humidified, making it less irritant to the nasal mucosal. The therapy is well established in neonatal and paediatric populations and HFNC use has recently been described in adult populations.

Background. High-flow nasal cannulae (HFNCs) create positive oropharyngeal airway pressure, but it is unclear how their use affects lung volume. Electrical impedance tomography allows the assessment of changes in lung volume by measuring changes in lung impedance. Primary objectives were to investigate the effects of HFNC on airway pressure (Paw) and end-expiratory lung volume (EELV) and to identify any correlation between the two. Secondary objectives were to investigate the effects of HFNC on respiratory rate, dyspnoea, tidal volume, and oxygenation; and the interaction between BMI and EELV.

Methods. Twenty patients prescribed HFNC post-cardiac surgery were investigated. Impedance measures, Paw/Pao2/Fio2 ratio, respiratory rate, and modified Borg scores were recorded first on low-flow oxygen and then on HFNC.

Results. A strong and significant correlation existed between Paw and end-expiratory lung impedance (EELI) (r=0.7, P<0.001). Compared with low-flow oxygen, HFNC significantly increased EELI by 25.6% [95% confidence interval (CI) 24.3, 26.9] and Paw by 3.0 cm H₂O (95% CI 2.4, 3.7). Respiratory rate reduced by 3.4 bpm (95% CI 1.7, 5.2) with HFNC use, tidal impedance variation increased by 10.5% (95% CI 6.1, 18.3), and Paw/Pao2/Fio2 ratio improved by 30.6 mm Hg (95% CI 17.9, 43.3). A trend towards HFNC improving subjective dyspnoea scoring (P=0.023) was found. Increases in EELI were significantly influenced by BMI, with larger increases associated with higher BMIs (P<0.001).

Conclusions. This study suggests that HFNCs reduce respiratory rate and improve oxygenation by increasing both EELV and tidal volume and are most beneficial in patients with higher BMIs.

Editor’s key points

- High-flow nasal cannulae (HFNCs) used for oxygen therapy increases pharyngeal airway pressures but the effect on lung volumes is unknown.
- In this study of patients after cardiac surgery, HFNC increased end-expiratory lung impedance, suggesting increased lung volumes and functional residual capacity.
- Oxygenation improved and the benefits were greatest in patients with high BMIs.
- Further data are required to assess the clinical significance of these data.

Keywords: lung, volume; oxygen, therapy; surgery, cardiovascular

Accepted for publication: 10 June 2011

© The Author [2011]. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com
A number of studies have described the generation of positive airway pressure at the level of the pharynx associated with HFNC. However, there are no data regarding the translation of this pharyngeal positive pressure effect to the lungs, nor any data describing associated changes in lung volumes. This is essential in understanding whether HFNC provide any clinically relevant benefit.

Electrical impedance tomography (EIT) is a non-invasive radiation-free bedside imaging technique used to provide real-time images and data of regional lung ventilation and lung volumes (Fig. 1). Its use has been validated in a number of clinical applications including optimization of mechanical ventilatory strategies such as lung recruitment manoeuvres; detection of pulmonary complications including lung collapse, pleural effusion, and pneumothorax; and ensuring correct placement of the endotracheal tube. EIT can provide an indication of changes in lung volumes associated with HFNC usage.

The primary aims of this prospective interventional study were to compare the differences in airway pressure \( (P_{aw}) \) and end-expiratory lung volume (EELV) between HFNC and low-flow oxygen and to determine any relationship between changes in \( P_{aw} \) and EELV. Secondary aims were to investigate the changes in respiratory rate, subjective rating of dyspnoea (modified Borg score), tidal volume \( (V_t) \), and oxygenation \( (P_{aO_2}/F_{I_{O_2}} \) ratio) between the two therapies. Owing to the association between increased BMI and decreased FRC in the postoperative period, we assessed the interaction between BMI and changes in EELV in patients receiving HFNC.

### Methods

After approval from the Institutional Human Research and Ethics Committee (EC27105), this study was conducted at a tertiary referral hospital in Australia specializing in cardiothoracic surgery and medicine. The study was registered with the Australian Clinical Trials Registry (Clinical Trial No.: ACTRN1260900037202).

### Participants

Written informed consent was obtained from all participants. Patients were included in the study if they were deemed by the treating intensive care specialist to be displaying signs of respiratory dysfunction including one or more of decreasing \( P_{aO_2} \) \( (P_{aO_2}/F_{I_{O_2}} \) ratio of <300), subjective dyspnoea, increased use of accessory muscles, increase in respiratory rate and requiring HFNC; post-cardiac surgery (performed on cardiopulmonary bypass); and ≥18 yr of age. Patients were excluded if they had ongoing air leak post-surgery, a requirement for electrical cardiac pacing or an open sternum.

### Electrical impedance tomography

Lung volume changes were assessed using EIT. Previous studies have demonstrated that changes in end-expiratory lung impedance (EELI) as measured by EIT have a strong linear correlation with changes in EELV. Similarly, \( V_t \) changes are correlated with tidal impedance variation \( (V_{ARt}) \). Therefore, the effect of HFNC at a pulmonary, rather than an oropharyngeal airway level, can be assessed.

EIT measurements were performed with the EIT Evaluation Kit 2 (Dräger Medical, Lübeck, Germany) which had been calibrated and self-tested according to the manufacturer’s instructions. EIT files were automatically saved to the device’s hard drive, analysed by the Dräger review software V5.1 and then downloaded as a Microsoft Excel spreadsheet.

### Study protocol

Patients were assessed in an upright position either in bed (at a head of bed elevation of at least 45° as measured by an angle measurement device) or sitting in a straight backed chair. Pain levels were assessed, and analgesia administered if necessary, to ensure that patients could breathe without discomfort and restriction. After instillation of Co-phenylcaine Forte Nasal spray into the nares, an 8 Fr feeding tube (Unomedical, Sydney, Australia) was inserted nasally to the level of the oropharynx. Correct placement was confirmed both by visual inspection and capnography (Marquette monitor, GE Medical Systems Information Technologies Inc., WI, USA). The tube was then connected to a precision pressure transducer (PPT-001, DWVV2V, Honeywell International Ltd, Minneapolis, MN, USA) to measure \( P_{aw} \) and the data downloaded directly to a Microsoft Excel spreadsheet. Figure 2 shows a representative example of the airway pressure tracing obtained.
An appropriately sized electrode belt was placed around the circumference of the patient’s chest, at the level of the anterior intercostal space 5–6, and an optimal EIT signal was confirmed before data collection. For female patients, the placement of the belt was standardized to underneath the breast tissue. Data were collected first on low-flow oxygen, then on HFNC. The order of data collection was unable to be randomized as the participants were requiring HFNC as part of their treatment. Before the measurement of the low-flow oxygen data, patients were asked to rate their dyspnoea level using the Modified Borg Dyspnoea Scale and asked to keep their mouth closed if possible during the measurement period. The patient's mouth status (open or closed) was tracked every 30 s during the measurement period. The patient’s mouth status (open or closed) was tracked every 30 s during the measurement period. Simultaneous 2 min \( P_{aw} \), EELI, and VARt readings were then recorded while the patient was receiving oxygen therapy via a low-flow system (either nasal cannula or Hudson face mask) at the flow rate the patient was receiving before HFNC prescription. \( F_{IO2} \), on low flow was estimated using a previously described standardized algorithm. An arterial blood gas (ABG) was taken at this time in all patients if an intra-arterial line (IAL) was in situ.

HFNCs (Optiflow™ system, MR850 heated humidified, RT202 delivery tubing and RT050/051 nasal cannulae, Fisher and Paykel Healthcare Ltd, Auckland, New Zealand) were applied with the humidifier temperature set to 37°C to optimize humidification. The \( F_{IO2} \) was titrated to patient need to maintain \( S_{P02} \) ≥95% and flow was commenced at 35 litre min\(^{-1}\). This flow rate was titrated upwards to a maximum of 50 litre \( \text{min}^{-1} \) as determined by patient tolerance, as is the clinical practice in the unit. A 15 min washout period was used between therapies to counter any cumulative treatment effect. The patient was again asked to score their dyspnoea while reminded to keep their mouth closed if possible. After optimal signals were confirmed on both the EIT and pressure transducer, simultaneous 2 min EIT and \( P_{aw} \) measurements were repeated in addition to ABG analysis.

Supplementary data included patient characteristics, including height and weight to assess BMI. Data analysed from the EIT files were EELI, VARt, and respiratory rate. The mean \( P_{aw} \) was measured in cm H\(_2\)O from the pressure transducer files.

Initially, the investigators chose to exclude patients requiring cardiac pacing as there was no safety data regarding the interaction between EIT and cardiac pacing. After consultation with colleagues who routinely use EIT to study post-cardiac surgical neonates with temporary epicardial pacing, it was found that in a 12 month period, no adverse events occurred. Therefore, late in the study, this exclusion criterion was removed. Only one patient was recruited using the amended exclusion criteria.

**Statistical analysis**

To investigate the changes in lung volumes (EELI and VARt) for the EIT data, a mixed-effects regression model was used. A mixed model extends a standard regression model by allowing repeated results from the same individual which we modelled using a random intercept. The dependent variable was EIT and the independent variable was HFNC (yes/no). Spearman’s correlation coefficient was used to determine any correlation between EELI and \( P_{aw} \) change. A second independent variable of mouth closed (yes/no) was added to test its effect on EELI. An interaction term was included to examine whether the effectiveness of the HFNC depended on BMI. To investigate changes in \( V_r \), respiratory rate, modified Borg score, and \( P_{ao2}/F_{IO2} \) ratio, a paired t-test was used. Adjustments were made for multiple comparisons using the Bonferroni method; therefore, any \( P \)-values <0.008 (0.05/6 outcome variables=0.008) were considered significant. Data were assessed using an intention-to-treat analysis. All analyses were performed using the R statistical software (www.r-project.org).

**Results**

Twenty-seven patients were eligible for inclusion into the study and were approached for informed consent. Two patients refused insertion of the nasopharyngeal catheter, two patients required epicardial pacing to be commenced just before the study period, one male patient could not be fitted with a correctly sized EIT belt due to their chest circumference, and the EIT was unable to pass the manufacturer’s self test in a further two patients. Therefore, 20 patients who were prescribed HFNC by the intensive care specialist post-cardiac surgery were recruited, 15 of whom were males. The mean (range) age of participants was 65.3 (51–77) yr, height was 171.1 (160–183) cm, weight was 93.3 (60–123) kg, and BMI was 32 (22–45) kg m\(^{-2}\). Selected clinical variables are shown in Table 1. Two patients were unable to provide complete data due to the absence of an IAL in one patient and the inability to tolerate the nasopharyngeal catheter in the other. Using an intention-to-treat analysis, the data from these two patients were included.

When compared with a low-flow oxygen device, HFNC increased mean \( P_{aw} \) by 3.0 cm H\(_2\)O [95% confidence interval (CI) 2.4, 3.7; paired t-test \( P<0.001 \)] and EELI by 1517...
impedance units (95% CI 1425, 1608; mixed model P<0.001) (Table 2). This translates to an increase in EELI of 25.6% (95% CI 24.3, 26.9; mixed model P<0.001) on HFNC, suggesting a similar increase in EELV. No statistically significant difference was found in EELI when the patients’ mouth was closed or open (mixed model P=0.99). No significant correlation was found between Paw and mouth open or closed (P=0.99). A strong and significant correlation was found between Paw and EELI (r=0.7, P<0.001).

Respiratory rate was lowered by 3.4 bpm (95% CI 1.7, 5.2; paired t-test P<0.001) and the Borg dyspnoea score by 0.8 points (95% CI 0.1, 1.4; paired t-test P=0.023). HFNC significantly increased VAr by 159 impedance units (95% CI 117, 202; mixed model P<0.001), translating to a 10.5% increase (95% CI 6.1, 18.3; mixed model P<0.001). This finding suggests a similar increase in Vt. The Paao2/Fio2 ratio was improved by 30.6 (95% CI 17.9, 43.3; paired t-test P<0.001) even though 95% of patients were receiving an equal or lower Fio2 while on HFNC than when on low-flow oxygen.

Higher gas flow rates were found to result in larger increases in EELI. For every 1 litre min⁻¹ increase in flow rate, the difference in EELI between low-flow oxygen device and HFNC increases by a further 0.7% (95% CI 0.1, 1.3; mixed model P-value=0.023).

BMI significantly influenced the positive effect of HFNC on EELI (mixed model P<0.001). A BMI of 25 resulted in a mean increase in EELI of 13.3% (high vs low flow), whereas with a BMI of 40, the increase was 24.4%. Figure 3 shows the mean increases in EELI (expressed as a percentage increase) by BMI.

### Table 1: Patient characteristics. CABG, coronary artery bypass graft; AVR, aortic valve replacement; MVR, mitral valve replacement

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>BMI</th>
<th>APACHE 2 Score</th>
<th>Surgery</th>
<th>Respiratory parameters on low-flow oxygen</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>32</td>
<td>10</td>
<td>CABG×3</td>
<td>Fio2, Paao2/Fio2, Respiratory rate</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>26</td>
<td>16</td>
<td>AVR, CABG×3</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>43</td>
<td>8</td>
<td>AVR, replacement of ascending aorta</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>45</td>
<td>16</td>
<td>AVR, replacement of aortic root</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>33</td>
<td>9</td>
<td>CABG×3</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>34</td>
<td>16</td>
<td>CABG×3, AVR</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>34</td>
<td>8</td>
<td>AVR</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>28</td>
<td>18</td>
<td>CABG×4</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>22</td>
<td>18</td>
<td>CABG×3, MVR</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>32</td>
<td>27</td>
<td>CABG×3</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>35</td>
<td>16</td>
<td>CABG×4</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>34</td>
<td>16</td>
<td>CABG×4</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>29</td>
<td>17</td>
<td>AVR</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>26</td>
<td>14</td>
<td>CABG×1</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>25</td>
<td>24</td>
<td>AVR, replacement of aortic root</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>36</td>
<td>10</td>
<td>CABG×4</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>M</td>
<td>34</td>
<td>20</td>
<td>CABG×4</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>F</td>
<td>34</td>
<td>12</td>
<td>CABG×2, MVR</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>F</td>
<td>24</td>
<td>18</td>
<td>CABG×4</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>31</td>
<td>15</td>
<td>CABG×2</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2: Outcome variables. Low-flow oxygen compared with HFNCs

<table>
<thead>
<tr>
<th>Variable</th>
<th>Low-flow oxygen [mean (SD)]</th>
<th>HFNC [mean (SD)]</th>
<th>Mean difference [mean (SD)]</th>
<th>95% confidence interval</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>End-expiratory lung impedance (units)</td>
<td>419 (212.5)</td>
<td>1936 (212.9)</td>
<td>1517 (46.6)</td>
<td>1425, 1608</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mean airway pressure (cm H2O)</td>
<td>-0.3 (0.9)</td>
<td>2.7 (1.2)</td>
<td>3.0 (1.3)</td>
<td>2.4, 3.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Respiratory rate (bpm)</td>
<td>20.9 (4.4)</td>
<td>17.5 (4.6)</td>
<td>-3.4 (2.8)</td>
<td>-2.0, -4.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Borg score</td>
<td>2.7 (2.6)</td>
<td>1.9 (2.3)</td>
<td>-0.8 (1.2)</td>
<td>-0.1, -1.4</td>
<td>0.023</td>
</tr>
<tr>
<td>Tidal variation (units)</td>
<td>1512 (195.0)</td>
<td>1671 (195.1)</td>
<td>159 (21.6)</td>
<td>117, 201</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Paao2/Fio2 ratio (mm Hg)</td>
<td>160 (53.7)</td>
<td>190.6 (57.9)</td>
<td>30.6 (25.9)</td>
<td>17.9, 43.3</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
Discussion

These data indicate for the first time that HFNC are associated with an increase in EELI in patients post-cardiac surgery, suggesting an increase in EELV and hence FRC. The increase in EELV was found to be significantly greater in those subjects with a higher BMI. The generation of positive oropharyngeal $P_{aw}$ by HFNC reported in earlier studies was confirmed. A significant increase in respiratory rate was recorded in addition to a trend towards decreasing subjective dyspnoea levels. Significant increases were recorded in $V_{t}$ and oxygenation. The benefits of positive airway pressure and the resultant increase in EELV include a reduction in work of breathing, prevention of small airway closure, and improved oxygenation due to reduced pulmonary shunting. This increase in EELV, coupled with the reduction in respiratory rate and the patients’ perceived dyspnoea, could mean that HFNC use after cardiac surgery may be of substantial clinical benefit in the patient with borderline respiratory function after extubation.

HFNC have been shown to generate between 0.2 and 4.8 cm H$_2$O of positive $P_{aw}$ in neonatal and paediatric populations. In healthy adult volunteers, HFNC generated between 5.1 and 8.7 cm H$_2$O pharyngeal $P_{aw}$. The findings of our study are similar to the only other published work investigating the effects of HFNC on $P_{aw}$ in adult intensive care patients. We found no significant correlation between $P_{aw}$ and mouth open or closed ($P=0.99$) in this study, which is at odds with previous studies. We believe that this may be due to the small sample of mouth open data leading to the data sample being underpowered to detect a difference in this variable (21% vs 79% of total data).

EELI was found to increase with the transition from low-to high-flow oxygen delivery in 90% of the participants in this study. Owing to the strong linear relationship between changes in EELI and EELV demonstrated in previous EIT studies, it can therefore be concluded that the use of HFNC increases EELV. This increase in EELV may be explained by the recruitment of alveoli, and prevention of further alveolar collapse, as a result of the low-level positive $P_{aw}$ generated by HFNC. Additionally, the increase could be attributed to further expansion of partially recruited alveoli.

With a mean BMI of 32 kg m$^{-2}$ in the study cohort, the increase in EELV was significantly greater in those patients with higher BMI (Fig. 3). Obese patients are predisposed to postoperative atelectasis and this atelectasis resolves more slowly than in patients with normal body weight. Additionally, this group of patients is prone to reduced FRC with an increased risk of developing further respiratory complications. Therefore, it appears that patients with higher BMIs may derive particular benefit from the low-level positive airway pressure and increase in EELV that HFNCs produce. This may be explained by the pre-existing derangement in respiratory mechanics displayed in obese patients, specifically the higher closing volumes and subsequent reduction in lung volume due to excessive unopposed intra-abdominal pressure. Subsequently, the obese patient will have a higher number of recruitable alveoli than a patient with a normal BMI and this may account for the beneficial effects seen in the obese group. More work in this area is required to further explore and describe the interaction observed between EELV and BMI, particularly as more than one third of patients undergoing cardiac surgery at this institution have a BMI of $\geq 30$.

A statistically significant reduction in respiratory rate was observed on HFNC. While no formal measurements of work of breathing were used, the mean decrease in respiratory rate of 3.4 bpm may result in a reduction in work of breathing. An improvement in lung compliance and FRC could be contributing factors in the trend towards an improvement in subjective dyspnoea and may also be partially responsible for the observed decrease in respiratory rate.

A higher $P_{aO_2}/F_{I_O_2}$ ratio was demonstrated in patients using HFNC. This could be attributed in part to the observed increase in EELV and resultant increase in alveolar ventilation. However, the $P_{aO_2}/F_{I_O_2}$ ratio would also be improved by the use of higher inspired oxygen concentration, as is seen in high-flow oxygen devices. During high flow, it is likely that there is less air entrainment, and this may also be a contributor. In our study, 95% of patients were receiving an equal or lower $F_{I_O_2}$ while on HFNC than when on low-flow oxygen, with 50% receiving a lower $F_{I_O_2}$ while on HFNC.

Gas flow rates, which determine inspired oxygen concentration particularly at lower flows, were not standardized across patients in this study. Instead, a clinically driven protocol was chosen which reflected clinical practice and management of these patients and clinical usage of the device. The assessment of the effects of HFNC at different flow rates may be of interest in future studies to further delineate optimal flows.

While the sample size of this study was small, the investigators were able to describe significant differences in clinical markers between low-flow oxygen and HFNC usage in a typical post-cardiac surgical cohort. A larger sample size will be necessary to investigate the effects of HFNC on longer term outcomes. Our cohort consisted of more males.
than females at a ratio of 3:1, which is reflective of global trends in cardiac surgery.\textsuperscript{32}

This study confirms that HFNCs are effective in providing modest levels of positive airway pressure and, for the first time, clearly demonstrates that this translates to increases in EELV. These increases in lung volume, and the associated improvements in respiratory rate, subjective dyspnoea, and oxygenation, necessitate further investigation if the clinical significance of HFNC usage and its impact on patients’ longer term outcomes is to be established. These questions will be addressed in a subsequent randomized controlled trial which will examine the effects of HFNC on postoperative atelectasis in patients with a BMI of $\geq 30$ (Australian Clinical Trials Registry, Clinical Trial No.: ACTRN12610000942055).

**Conclusions**

HFNCs generate statistically and clinically relevant increases in oropharyngeal airway pressure and increases in EELV and tidal volume as demonstrated by changes in lung impedance, particularly in patients with higher BMIs. These changes are associated with reduced respiratory rate, less dyspnoea, and improved oxygenation. Thus, HFNC may be a useful treatment option for patients experiencing respiratory dysfunction post-cardiac surgery, particularly those patients who cannot tolerate non-invasive ventilation and those with a higher BMI.

**Acknowledgement**

We would like to thank Eckhard Teschner from Dräger Medical, Lübeck, Germany, for his technical advice with the electrical impedance tomograph.

**Conflict of interest**

None declared.

**Funding**

This work was partially supported by an unrestricted grant from Fisher and Paykel Healthcare Ltd. They also supplied a loan Honeywell pressure transducer, two heated humidifiers, two bird blenders, and consumables. Fisher and Paykel Healthcare Ltd had no part in study design, data collection, data analysis, or creation of the manuscript. J.F.F., L.R.C., and A.C. have received assistance from Fisher and Paykel Healthcare Ltd to support travel and accommodation costs to attend two research meetings.

**References**

1. Ng CS, Wan S, Yim AP, Arifi AA. Pulmonary dysfunction after cardiac surgery. *Chest* 2002; **121**:1269–77
10. McGinley BM, Patil SP, Kirkness JP, Smith PL, Schwartz AR, Schneider H. A nasal cannula can be used to treat obstructive sleep apnea. *Am J Respir Crit Care Med* 2007; **176**:194–200
20. Jones RL, Nzekwu MM. The effects of body mass index on lung volumes. *Chest* 2006; **130**:827–33
High-flow nasal cannulae use post-cardiac surgery

31 Otis AB. The work of breathing. Physiol Rev 1954; 34: 449–58